AbbVie records a $3.5 billion impairment charge following the failure of emraclidine in Phase II schizophrenia trials.

US biopharma Biohaven and Dutch biotech Merus have announced a research collaboration and license agreement to co-develop ...

City Therapeutics partners with Bausch + Lomb to develop an RNAi-based therapy for geographic atrophy, leveraging City’s RNAi ...

Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...

Teva partners with Klinge Biopharma and Formycon to commercialize FYB203, an Eylea biosimilar, as Ahzantive in Europe and ...

New export figures for November from Statistics Denmark show that medicine constitutes a significant part of total Danish ...

A clinical-stage biopharma company focused on developing therapies for obesity and other cardiometabolic disorders.

China’s National Medical Products Administration (NMPA) has approved French Pharma major Sanofi’s Sarclisa (isatuximab), an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) ...

Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label ...

Sage Therapeutics’ shares jumped over 45% to $8.09 in after-hours on Friday, after the company confirmed that biotech major ...

South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...

Mountainfield Venture Partners and Keymed Biosciences launch Timberlyne Therapeutics with $180 million in series A funding.